Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion

Crispr Therapeutics AG

03/08/2026 21:26

Overview
Switzerland-U.S. gene-editing firm's Q2 CASGEVY revenue rose 151% yr/yr to $76 mln
Q2 net loss narrowed to $91 mln from $209 mln a year earlier
FDA approved CASGEVY for children as young as 2 with SCD or TDT

Outlook
Company expects clinical updates on CTX310 and CTX611 in the second half of 2026
CRISPR Therapeutics anticipates further updates on zugo-cel autoimmune and immuno-oncology programs in H2 2026
Company says regulatory submissions for CASGEVY in children are completed in KSA and UK; access efforts ongoing

Result Drivers
CASGEVY APPROVAL EXPANSION - FDA approval for children as young as 2 years old with SCD or TDT increased eligible patient pool and contributed to revenue growth
REIMBURSEMENT PROGRESS - Vertex secured reimbursement for CASGEVY for eligible patients in Germany, with efforts underway globally to expand access
OPERATING COST REDUCTION - Decrease in R&D and G&A expenses helped narrow net loss, mainly due to lower employee-related and facility costs

Company press release: ID:nGNXbCXn25

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.94
 
Q2 Loss Per Basic Share
 
$0.94
 
Q2 Operating Expenses
 
$127.45 mln
 
Q2 Pretax Loss
 
$90.19 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

Reuters Recommended Reads
Aug 3 - Vertex raises annual revenue forecast on cystic fibrosis drugs strength 
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
Aug 3 - Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)